As JAK inhibitors have only recently become available for prescription by a dermatologist or healthcare professional experienced in the diagnosis and treatment of alopecia areata, the reimbursement situation is evolving. It may take some time for insurance companies to add Olumiant® and/or Litfulo® to their list of covered prescription drugs. Private and public drug plans may require some time to develop reimbursement policies for this treatment. If you submit private insurance coverage through your employer and your provider denies coverage, consider submitting again in three months to see if your coverage has changed.

If you are prescribed one of the newer JAK inhibitors, your healthcare professional may provide you with the details of any patient support programs and/or resources provided by the drug’s manufacturer which can help you with reimbursement.

Pfizer offers assistance programs for some patients who cannot afford out-of-pocket medication costs despite their insurance coverage. Please speak to your health care provider about Pfizer’s assistance programs. Please direct any Litfulo® specific question to Pfizer’s medical information line (including questions about public/private coverage): 1-800-463-6001. More information can be found on the Pfizer website. 

Lilly offers a Patient Support Program for eligible patients. Patients with questions regarding Olumiant® and/or its coverage can call the Lilly Customer Response Centre at 1-888-545-5972.